Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

585 results

• PTCLIndependent statistical analysis of Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00865969).Phase 2Results postedn = 129NCT00865969
• PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin’s Lymphoma That Have Not Responded to Standard Treatment: Complete Statistical AnalysisIndependent statistical analysis of PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 17NCT01581541
• Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia: Complete Statistical AnalysisIndependent statistical analysis of Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 48NCT03476330
• R-CHOPIndependent statistical analysis of Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 57NCT00450385
• Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 69NCT01059786
• Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP: Complete Statistical AnalysisIndependent statistical analysis of Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 8NCT00220727
• Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2: Complete Statistical AnalysisIndependent statistical analysis of Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 55NCT01200485
• Rasburicase in Patients at Risk for Tumor Lysis Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Rasburicase in Patients at Risk for Tumor Lysis Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00628628).Phase 2Results postedn = 82NCT00628628
• REACH 5Independent statistical analysis of Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 46NCT03774082
• Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928030).Phase 1/2Results postedn = 3NCT01928030
• Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase EARLY_1Results postedn = 22NCT04476277
• RED-HFIndependent statistical analysis of the RED-HF phase 3 trial of darbepoetin alfa in heart failure, including trial design, time-to-event endpoints, hazard ratios, KCCQ analyses, safety, methodology, and statistical interpretation.Phase 3Results postedn = 2,278NCT00358215
• REDIRECTIndependent statistical analysis of Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 108NCT04101331
• Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission: Complete Statistical AnalysisIndependent statistical analysis of Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 17NCT00045435
• Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease: Complete Statistical AnalysisIndependent statistical analysis of Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease: primary endpoint results, effect…Phase 2Results postedn = 71NCT00448201
• Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 17NCT00045305
• Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers: Complete Statistical AnalysisIndependent statistical analysis of Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 15NCT01135329
• ReTHINKIndependent statistical analysis of Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 49NCT02598297
• RISE-MIndependent statistical analysis of Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03634800).Phase 2Results postedn = 6NCT03634800
• RVD LiteIndependent statistical analysis of Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01782963).Phase 2Results postedn = 50NCT01782963
• RVDDIndependent statistical analysis of Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 74NCT00724568
• SCNSL1Independent statistical analysis of High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 40NCT00801216
• SEAMLESSIndependent statistical analysis of A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 482NCT01303796
• SIGNATUREA detailed statistical analysis of the phase 2 SIGNATURE trial evaluating ceritinib in patients with tumors with aberrations in ALK or ROS1, including trial design, RECIST 1.1 endpoints, planned statistical methods, safety,…Phase 2Results postedn = 47NCT02186821
• SIGNATUREIndependent statistical analysis of LDE225 for Patients With PTCH1 or SMO Mutated Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02002689).Phase 2Results postedn = 10NCT02002689
• STOMPIndependent statistical analysis of STOMP (NCT02343042), a randomized phase 1/2 study evaluating selinexor with backbone treatments in patients with multiple myeloma, including dose-escalation, pharmacokinetic, response, and duration-of-response endpoints.Phase 1/2n = 300NCT02343042
• STORMIndependent statistical analysis of the STORM phase 2 trial of selinexor and dexamethasone in multiple myeloma, including its non-randomized design, overall response rate endpoint, statistical methodology, and safety reporting.Phase 2Results postedn = 202NCT02336815
• SWEDESIndependent statistical analysis of Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 205NCT00806403
• TOPSIndependent statistical analysis of Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity): primary endpoint results, effect…Phase 3Results postedn = 476NCT00124748
• TRAILIndependent statistical analysis of Letrozole for Lymphangioleiomyomatosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01353209).Phase 2Results postedn = 17NCT01353209
• TRANSCEND NHL 001An independent statistical analysis of TRANSCEND NHL 001 (NCT02631044), evaluating JCAR017 single-dose and 2-dose schedules in B-cell non-Hodgkin lymphoma, with emphasis on safety, dose-limiting toxicity, and objective response rate.Phase 1n = 387NCT02631044
• TRANSFORMIndependent statistical analysis of the randomized phase 3 TRANSFORM trial of JCAR017 versus standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas.Phase 3Results postedn = 184NCT03575351
• VENICE IIIndependent statistical analysis of A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer…Phase 3Results postedn = 210NCT02980731
• VitalpsIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 23NCT02104505
• VOYAGEIndependent statistical analysis of Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 244NCT02152956

← All therapeutic areas